Venclexta trial deaths force AbbVie, Roche to stop recruiting myeloma patients

AbbVie and Roche are looking to move key oncology drug Venclexta deeper into the blood cancer arena, but their ambitions in multiple myeloma just took a hit. The FDA has halted enrollment in all of Venclexta’s myeloma trials, the companies said Tuesday. The reason? The Venclexta arm of a phase 3 study, dubbed Bellini, turned up a higher… Read More »

Genetics Home Reference: hyaline fibromatosis syndrome

Hyaline fibromatosis syndrome is a disorder in which a clear (hyaline) substance abnormally accumulates in body tissues. This disorder affects many areas of the body, including the skin, joints, bones, and internal organs. The severity of the signs and symptoms of hyaline fibromatosis syndrome fall along a spectrum. In more severe cases (previously diagnosed as… Read More »